Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956866 | 0.84 | FGFR1 (0.56) | FGFR1FGFR4SCN9AALDH1A1 | |
| SCHEMBL2797578 | 0.83 | ENPP3 (0.39) | FGFR1FGFR4NOTUMSCN9ASCN5A | |
| SCHEMBL23107520 | 0.83 | NOTUM (0.47) | NOTUMSCN9ASCN5AKCNH2HSD17B10 | |
| SCHEMBL15712169 | 0.83 | NOTUM (0.47) | NOTUMSCN9ASCN5AKCNH2HSD17B10 | |
| SCHEMBL29193676 | 0.83 | NOTUM (0.50) | NOTUMSCN9ASCN5AKCNH2HSD17B10 | |
| SCHEMBL16888474 | 0.81 | ABL1 (0.49) | FGFR1FGFR4ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL30368614 | 0.79 | MAPK14 (0.51) | NOTUMSCN9ASCN5AKCNH2MEN1 | |
| SCHEMBL23108729 | 0.79 | NOTUM (0.44) | NOTUMSCN9ASCN5AKCNH2HSD17B10 | |
| SCHEMBL24498840 | 0.79 | MAPK14 (0.51) | NOTUMSCN9ASCN5AKCNH2MEN1 | |
| SCHEMBL26961002 | 0.78 | NOTUM (0.41) | FGFR1FGFR4NOTUMSCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023194840-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN COVID-19 | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194841-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN ULCERATIVE COLITIS | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194842-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN RHEUMATOID ARTHRITIS | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4225442-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Unichem Laboratories Ltd (IN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116547283-A | Substituted tricyclic compounds | 联合化学实验室有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022074572-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD (IN) | 2022-04-14 | — | — | WO | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | FGFR1 4836/4885FGFR4 4606/4885NOTUM 2985/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | FGFR1 2711/4885FGFR4 4675/4885NOTUM 2365/4885 |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | PSAP, ABCG2, PSAT1 | FGFR1 4558/4885FGFR4 4237/4885NOTUM 1515/4885 |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | CCNY, CNKSR1, CDK1 | FGFR1 372/4885FGFR4 1487/4885NOTUM 3654/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | FGFR1 4835/4885FGFR4 4624/4885NOTUM 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.